Simon Hughes

Simon Hughes

Auto-generated profile, based on publicly available information

Simon Hughes

Guy's Cancer, Guy's & St. Thomas' NHS Foundation Trust, United Kingdom; School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CMC. Moss
C. Moss
AHA. Haire
A. Haire
FCF. Cahill
F. Cahill
DED. Enting
D. Enting
SHS. Hughes
S. Hughes
Mieke Van HemelrijckMieke Van Hemelrijck
Mieke Van Hemelrijck
Background: The burden of disease due to cancer remains substantial. Since the value of real-world evidence has also been recognised by regulatory agencies, we established a Research Ethics Committee (REC) approved research database for cancer patients (Reference: 18/NW/0297). Construction and content: Guy’s Cancer Cohort introduces the concept of opt-out consent processes for research in a subset of oncology patients diagnosed and treated at a large NHS Trust in the UK. From April 2016 until March 2017, 1388 eligible patients visited Guy’s and St Thomas’ NHS Foundation Trust (GSTT) for breast cancer management. For urological cancers this number was 1757 and for lung cancer 677. The Cohort consists of a large repository of routinely collected clinical data recorded both retrospectively and prospectively. The database contains detailed clinical information collected at various timepoints across the treatment pathway inclusive of diagnostic data, and data on disease progression, recurrence and survival. Conclusions: Guy’s Cancer Cohort provides a valuable infrastructure to answer a wide variety of research questions of a clinical, mechanistic, and supportive care nature. Clinical research using this database will result in improved patient safety and experience. Guy’s Cancer Cohort promotes collaborative research and will accept applications for the release of anonymised datasets for research purposes.

7 March 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
LMLiam Mannion
Liam Mannion
CBCecilia Bosco
Cecilia Bosco
RNRajesh Nair
Rajesh Nair
VMVinod Mullassery
Vinod Mullassery
DEDeborah Enting
Deborah Enting
SHSimon Hughes
Simon Hughes

11 October 2024 in BJUI Compass
Verified
Journal Article
Open access
LMLiam Mannion
Liam Mannion
VWVerity Watson
Verity Watson
VMVinod Mullassery
Vinod Mullassery
RNRajesh Nair
Rajesh Nair
TCThomas Charlton
Thomas Charlton
SHSimon Hughes
Simon Hughes
Background: When faced with treatment options, patients are asked to participate in decision‐making. We sought to determine which treatment aspects matter most for individuals treated for muscle invasive bladder cancer (MIBC), with an aim to improve understanding of patient preferences and what trade‐offs patients are willing to accept. Our study consisted of a discrete choice experiment (DCE): a type of questionnaire used to elicit preferences in the absence of real‐world choice.Methods: The DCE had five attributives, each with three levels. Participants were asked to complete a questionnaire in which they were asked to choose between two hypothetical MIBC treatments. The data were analysed using a conditional logit model, and preferences for, and trade‐offs between, attributes were estimated.Results: We recruited patients with MIBC who had either already completed, were undergoing or had yet to commence radical treatment for MIBC (n = 60). Participants indicated a strong preference for treatments that increased their life expectancy (p = <0.001), had a lower risk of long‐term complications (p = <0.001) and less changes to their body image (p = <0.001). Changes to sexual wellbeing (p = 0.09) or an increase in acute side effects (p = 0.99) did not influence preferences. Patients were willing to accept treatments with higher risk of long‐term complications to improve their life expectancy or body image.Conclusion: When deciding on the type of treatment, increased life expectancy is the most important consideration for people with MIBC. The risk of long‐term complications and changes to overall body image as a result of treatment are also important. Our study also highlighted that patients are willing to accept a higher risk of long‐term complications to improve other treatment outcomes. Understanding patient preferences is important for shared decision‐making, which has an impact on quality of care for people living with MIBC.

3 October 2024 in BJUI Compass
Verified
Journal Article
Open access
SHSimon Hughes
Simon Hughes
RNRajesh Nair
Rajesh Nair
BRBhav Radia
Bhav Radia
RMRavimohan S. Mavuduru
Ravimohan S. Mavuduru
PDProkar Dasgupta
Prokar Dasgupta
AGAmit Ghose
Amit Ghose
No pan‐India‐specific guidelines exist for the management of urological cancers. Although western guidelines are useful for informing management strategies, they do not account for the nuances of management in the Indian context. A modified Delphi method was used to provide a framework for the systematic development of India‐centric guidelines for the management of three uro‐oncology disease states: small renal masses, non‐muscle invasive bladder cancer and high‐risk/locally advanced prostate cancer.

7 November 2025 in Clinical Oncology
Verified
Journal Article
Open access
THT. Hope-Johnson
T. Hope-Johnson
GPG.B. Prajogi
G.B. Prajogi
EAE. Addison
E. Addison
ACA. Cameron
A. Cameron
BMB. Chanda M'ULe
B. Chanda M'ULe
AAA. Aggarwal
A. Aggarwal
Digital learning tools designed to improve radiotherapy contouring skills could help to increase training capacity in low- and middle-income countries (LMICs), where trainees face barriers to learning such as few clinicians and high workloads. Previous efforts to implement software to remotely review radiotherapy plans in LMICs have faced challenges such as poor internet connectivity and insufficient information technology infrastructure. We developed and evaluated a new cloud-based software to support radiotherapy planning, designed specifically for use in lower-resourced settings. A cloud-based training software, 'ACE-RT', was co-designed with radiotherapy professionals in Ghana, Zambia and the United Kingdom to facilitate remote feedback on contours and form a portfolio to record a clinician's skill development. The co-development involved assessing bandwidth, user interface, and functionality to meet needs in an LMIC setting. The software is noncommercial, designed for educational use. ACE-RT was evaluated by a radiation oncology consultant and trainee in Indonesia between April and September 2023. The resident successfully uploaded and received feedback on six plans over the evaluation period. Both consultant and trainee found ACE-RT made it easier to provide and receive tailored feedback compared to their previous practice and that the quality of feedback improved. The trainee reported that the quantity of feedback was greater when using ACE-RT. Both found the portfolio function useful, appreciating the educational value of reviewing previous contours. The main implementation barriers identified were poor internet connectivity and the complexity of exporting files from the treatment planning system. This evaluation of a cloud-based educational portfolio tool to improve training in radiotherapy contouring found it to be feasible, acceptable, and appropriate for use in a resource-limited setting. Unstable internet connectivity was the main barrier identified. Further work is recommended to improve the software's performance with variable internet speeds and evaluate the implementation in a range of centres.